Want to see KROS full AI Analyst Report?
KROS Stock Chart & Stats
$11.12
$0.28(2.78%)
At close: 4:00 PM EDT
$11.12
$0.28(2.78%)
Day’s Range― - ―
52-Week Range$9.69 - $22.55
Previous CloseN/A
Volume34.91K
Average Volume (3M)188.18K
Market Cap
$225.24M
Enterprise Value-$30.02
Total Cash (Recent Filing)$257.61M
Total Debt (Recent Filing)$15.72M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Nov 11, 2026EPS Estimate
-0.94Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.70
Shares Outstanding19,827,188
10 Day Avg. Volume156,465
30 Day Avg. Volume188,177
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.50
Price to Sales (P/S)3.11
P/FCF Ratio7.15
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$18.80Price Target Upside69.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-5.54
Revenue Forecast (FY)$16.37M
Bulls Say, Bears Say
Bulls Say
Liquidity RunwayThe projected funding runway into the second half of 2028 gives Keros time to advance clinical programs without relying immediately on another financing. This supports strategic flexibility, reduces near-term dilution pressure, and provides greater capacity to absorb development setbacks.
Takeda Partnership ProgressThe Takeda collaboration has progressed into a Phase 3 trial, providing external validation and a potentially important path toward commercialization for elritercept. The agreement also offers additional milestone potential and tiered royalties, creating longer-term economic leverage beyond current revenue.
Low Financial LeverageLow leverage and a substantial equity base are favorable for a research-intensive biotechnology company whose cash needs can fluctuate with clinical development. Limited debt reduces fixed financial obligations and preserves flexibility to direct resources toward pipeline advancement.
Bears Say
Unstable Revenue BaseThe sharp reversal in revenue shows that recent earnings power is not yet durable and depends heavily on non-recurring or milestone-style payments. Such volatility makes operating performance difficult to forecast and leaves future funding needs sensitive to development timing.
Persistent Cash BurnThe return to substantial operating and free-cash-flow consumption indicates that Keros is not currently self-funding its research activities. If positive cash generation does not recur, ongoing clinical investment could eventually require additional capital and reduce financial flexibility.
CFO TransitionA change in chief financial leadership introduces execution and continuity risk while Keros manages volatile revenue, cash usage, and clinical funding requirements. Although the departure was described as voluntary and without disputes, the interim arrangement leaves a permanent succession task unresolved.
Keros Therapeutics News
KROS FAQ
What was Keros Therapeutics’s price range in the past 12 months?
Keros Therapeutics lowest stock price was $9.69 and its highest was $22.55 in the past 12 months.
What is Keros Therapeutics’s market cap?
Keros Therapeutics’s market cap is $225.24M.
When is Keros Therapeutics’s upcoming earnings report date?
Keros Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 52 days.
How were Keros Therapeutics’s earnings last quarter?
Keros Therapeutics released its earnings results on Aug 03, 2026. The company reported -$1.45 earnings per share for the quarter, missing the consensus estimate of -$1.34 by -$0.11.
Is Keros Therapeutics overvalued?
According to Wall Street analysts Keros Therapeutics’s price is currently Undervalued.
Does Keros Therapeutics pay dividends?
Keros Therapeutics does not currently pay dividends.
What is Keros Therapeutics’s EPS estimate?
Keros Therapeutics’s EPS estimate is -0.94.
How many shares outstanding does Keros Therapeutics have?
Keros Therapeutics has 19,827,188 shares outstanding.
What happened to Keros Therapeutics’s price movement after its last earnings report?
Keros Therapeutics reported an EPS of -$1.45 in its last earnings report, missing expectations of -$1.34. Following the earnings report the stock price went up 1.385%.
Which hedge fund is a major shareholder of Keros Therapeutics?
Currently, no hedge funds are holding shares in KROS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Keros Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.80 (69.06% Upside)
$18.80 (69.06% Upside)
Blogger Sentiment
Neutral
KROS Sentiment 50%
Sector Average 63%
Sector Average 63%
Insider Transactions
Sold Shares
Worth $49.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.23%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-62.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Keros Therapeutics
Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.
KROS Stock 12 Month Forecast
Average Price Target
$18.80
▲(69.06% Upside)
Technical Analysis
Gyre Therapeutics
―
―
Palvella Therapeutics
―
Nurix Therapeutics
―
Bicara Therapeutics Inc.
―
Ownership Overview
5.19% Insiders
19.54% Mutual Funds
21.63% Other Institutional Investors
39.53% Public Companies and
Individual Investors